Revaprazan Hydrochloride; Uses, Dosage, Side Effects

Revaprazan Hydrochloride; Uses, Dosage, Side Effects

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity.It is a drug that reduces gastric acid secretion which is used for the treatment of gastritisIt acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

Mechanism of Revaprazan Hydrochloride

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritisIt acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

 

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritisIt acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritisIt acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea, but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively

You Might Also Like   Palbociclib Indications, Contraindications, Warnings

……………………information not available & the product goes to under development, or trialing. Further information

References

  1. https://pubchem.ncbi.nlm.nih.gov

Revaprazan Hydrochloride

About the author

Translate »